Acute coronary syndrome in patients with atrial fibrillation: what is the benefit/risk profile of triple antithrombotic therapy?
نویسنده
چکیده
What We Know Dual antiplatelet therapy is the recommended treatment for all patients with an acute coronary syndrome treated or not treated with an invasive procedure.1–4 Several trials testing clopidogrel5–7 or new antiplatelet agents8,9 clearly showed that the addition of a thyenopiridine to aspirin is associated with a significant improvement of patients’ outcomes. Furthermore, even in the case of elective percutaneous coronary procedures, the use of dual antiplatelet therapy is recommended for a medium-long period of time after the procedure.2,4,10
منابع مشابه
Balancing Antiplatelet and Anticoagulant Therapies in Patients with Cardiovascular Disease
Anticoagulation is needed for stroke prevention in patients with atrial fibrillation. Antiplatelet therapy is essential for the prevention of stent thrombosis and the reduction of cardiovascular events in patients who undergo coronary stenting and suffer acute coronary syndromes. When these conditions overlap, the individual antithrombotic strategies are commonly combined, and the efficacy bene...
متن کاملTriple Antithrombotic Therapy: Risky but Sometimes Necessary Tratamiento antitrombótico combinado triple: arriesgado pero a veces necesario
Antithrombotic therapy is the fundamental treatment for various cardiovascular conditions, e.g. ischemic heart disease, atrial fibrillation (AF), and stroke to prevent thrombotic complications and death. Dual antiplatelet inhibition with acetylsalicylic acid (ASA) and a P2Y12 inhibitor has proven most effective in patients with recent myocardial infarction (MI) or after percutaneous coronary in...
متن کاملTriple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting: Searching for the Best Combination.
Patients with atrial fibrillation (AF) who are treated with oral anticoagulants often have concurrent coronary artery disease. Triple oral antithrombotic therapy (TOAT) is often necessity to prevent stent thrombosis or myocardial infarction associated with percutaneous coronary intervention or acute coronary syndrome in patients with comorbid coronary artery disease and AF. Although the use of ...
متن کاملTriple antithrombotic therapy in cardiac patients: more questions than answers.
Many cardiac patients require combined antithrombotic therapy consisting of an anticoagulant and inhibition of platelet function. The most frequent indications are atrial fibrillation (AF) in combination with drug-eluting stent implantation and/or the presence of an acute coronary syndrome (ACS). Currently, the optimal combination of anticoagulants and anti-platelet therapy is unknown, but it i...
متن کاملTriple antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting: hovering among bleeding risk, thromboembolic events, and stent thrombosis
Dual antiplatelet treatment with aspirin and clopidogrel is the antithrombotic treatment recommended after an acute coronary syndrome and/or coronary artery stenting. The evidence for optimal antiplatelet therapy for patients, in whom long-term treatment oral anticoagulation is mandatory, is however scarce. To evaluate the safety and efficacy of the various antithrombotic strategies adopted in ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Circulation
دوره 126 10 شماره
صفحات -
تاریخ انتشار 2012